ENDS EVALI VALI THCVALI: Difference between revisions
| Line 14: | Line 14: | ||
===2021 (Declined): [https://drive.google.com/file/d/13QvkPs5oK8MF_CWmO5SL9mCwUcTmFMwR/view Letter from: Peter Briss, MD, MPH, EVALI Incident Manager, 2019-2020, Medical Director, National Center for Chronic Disease Prevention and Health Promotion, CDC]=== | ===2021 (Declined): [https://drive.google.com/file/d/13QvkPs5oK8MF_CWmO5SL9mCwUcTmFMwR/view Letter from: Peter Briss, MD, MPH, EVALI Incident Manager, 2019-2020, Medical Director, National Center for Chronic Disease Prevention and Health Promotion, CDC]=== | ||
*Given the lack of evidence to rule out the contribution of other chemicals of concern to the EVALI outbreak, the possibility that chemicals of concern could be introduced into supply chains of either THC or non-THC-containing products in the future, the prudence of assessing substance use broadly where clinically indicated, and that some EVALI cases reported exclusive use of nicotine-containing products, CDC declines to rename EVALI. | *Given the lack of evidence to rule out the contribution of other chemicals of concern to the EVALI outbreak, the possibility that chemicals of concern could be introduced into supply chains of either THC or non-THC-containing products in the future, the prudence of assessing substance use broadly where clinically indicated, and that some EVALI cases reported exclusive use of nicotine-containing products, CDC declines to rename EVALI. | ||
===2021: [https://twitter.com/mikepesko/status/1468932559098757127 Mike Pesko]=== | |||
Thread on X (formerly Twitter) about the letters. | |||
===2026 (Request): [https://drive.google.com/file/d/13QvkPs5oK8MF_CWmO5SL9mCwUcTmFMwR/view Letter to: Jay Bhattacharya, Acting Director - Centers for Disease Control and Prevention]=== | ===2026 (Request): [https://drive.google.com/file/d/13QvkPs5oK8MF_CWmO5SL9mCwUcTmFMwR/view Letter to: Jay Bhattacharya, Acting Director - Centers for Disease Control and Prevention]=== | ||